Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol

Schünemann, Holger J, Ventresca, Matthew, Crowther, Mark, Briel, Matthias, Zhou, Qi, Garcia, David, Lyman, Gary, Noble, Simon Ian Robert ORCID: https://orcid.org/0000-0001-5425-2383, MacBeth, Fergus, Griffiths, Gareth, DiNisio, Marcello, Iorio, Alfonso, Beyene, Joseph, Mbuagbaw, Lawrance, Neumann, Ignacio, Van Es, Nick, Brouwers, Melissa, Brozek, Jan, Guyatt, Gordon, Levine, Mark, Moll, Stephan, Santesso, Nancy, Streiff, Michael, Baldeh, Tejan, Florez, Ivan, Gurunlu Alma, Ozlem, Solh, Ziad, Ageno, Walter, Marcucci, Maura, Bozas, George, Zulian, Gilbert, Maraveyas, Anthony, Lebeau, Bernard, Buller, Harry, Evans, Jessica, McBane, Robert, Bleker, Suzanne, Pelzer, Uwe and Akl, Elie A. 2016. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open 6 (4) , e010569. 10.1136/bmjopen-2015-010569

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (862kB) | Preview

Abstract

INTRODUCTION: Parenteral anticoagulants may improve outcomes in patients with cancer by reducing risk of venous thromboembolic disease and through a direct antitumour effect. Study-level systematic reviews indicate a reduction in venous thromboembolism and provide moderate confidence that a small survival benefit exists. It remains unclear if any patient subgroups experience potential benefits. METHODS AND ANALYSIS: First, we will perform a comprehensive systematic search of MEDLINE, EMBASE and The Cochrane Library, hand search scientific conference abstracts and check clinical trials registries for randomised control trials of participants with solid cancers who are administered parenteral anticoagulants. We anticipate identifying at least 15 trials, exceeding 9000 participants. Second, we will perform an individual participant data meta-analysis to explore the magnitude of survival benefit and address whether subgroups of patients are more likely to benefit from parenteral anticoagulants. All analyses will follow the intention-to-treat principle. For our primary outcome, mortality, we will use multivariable hierarchical models with patient-level variables as fixed effects and a categorical trial variable as a random effect. We will adjust analysis for important prognostic characteristics. To investigate whether intervention effects vary by predefined subgroups of patients, we will test interaction terms in the statistical model. Furthermore, we will develop a risk-prediction model for venous thromboembolism, with a focus on control patients of randomised trials. ETHICS AND DISSEMINATION: Aside from maintaining participant anonymity, there are no major ethical concerns. This will be the first individual participant data meta-analysis addressing heparin use among patients with cancer and will directly influence recommendations in clinical practice guidelines. Major cancer guideline development organisations will use eventual results to inform their guideline recommendations. Several knowledge users will disseminate results through presentations at clinical rounds as well as national and international conferences. We will prepare an evidence brief and facilitate dialogue to engage policymakers and stakeholders in acting on findings

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Uncontrolled Keywords:	cancer; deep vein thrombosis; individual participant data meta-analysis; low molecular weight heparin; mortality; protocol.
Publisher:	BMJ Publishing Group
ISSN:	2044-6055
Date of First Compliant Deposit:	13 December 2017
Date of Acceptance:	10 December 2015
Last Modified:	05 May 2023 01:14
URI:	https://orca.cardiff.ac.uk/id/eprint/103887

Citation Data

Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item